Literature DB >> 15273267

Risk factors for hepatitis C infection and perception of antibody status among male prison inmates in the Hepatitis C Incidence and Transmission in Prisons Study cohort, Australia.

Jennifer A Gates1, Jeffrey J Post, John M Kaldor, Yong Pan, Paul S Haber, Andrew R Lloyd, Kate A Dolan.   

Abstract

The objective of this study was to compare the prevalence of risk factors for hepatitis C virus (HCV) infection among male prison inmates enrolling into a prospective cohort in Australia. We tested 121 inmates who were previously untested or were previously known to be anti-HCV antibody negative for anti-HCV antibodies by enzyme-linked immunosorbent assay. HCV-positive inmates were classified as cases (n = 25) and HCV-negative inmates as controls (n = 96). The study found that cases were less educated than controls and confirmed that prior imprisonment, drug injection, and a longer duration of injecting were risk factors for HCV infection. More than half of those who tested HCV positive perceived that they did not have HCV infection, and 44% were unsure of their HCV status. Those inmates who were incorrect about their HCV status tended to be less educated and were more likely to have been previously imprisoned than those who were correct about their HCV status. Inmates who were unsure of their HCV status were less likely to have been tested for HCV than those who had a clear perception of their HCV status, even if incorrect. Three (12%) inmates who tested positive denied injecting drug use, but reported other risk factors. Prisons are likely to remain an important site for the diagnosis of HCV infection and targeted interventions aimed at risk reduction among inmates with low education levels and a previous imprisonment history.

Entities:  

Mesh:

Year:  2004        PMID: 15273267      PMCID: PMC3455941          DOI: 10.1093/jurban/jth129

Source DB:  PubMed          Journal:  J Urban Health        ISSN: 1099-3460            Impact factor:   3.671


  11 in total

1.  Accuracy of perceptions of hepatitis B and C status: cross sectional investigation of opiate addicts in treatment.

Authors:  D Best; A Noble; E Finch; M Gossop; C Sidwell; J Strang
Journal:  BMJ       Date:  1999-07-31

2.  Acute hepatitis C virus infection in an Australian prison inmate: tattooing as a possible transmission route.

Authors:  J J Post; K A Dolan; L R Whybin; I W Carter; P S Haber; A R Lloyd
Journal:  Med J Aust       Date:  2001-02-19       Impact factor: 7.738

3.  Hepatitis B and C in New South Wales prisons: prevalence and risk factors.

Authors:  T G Butler; K A Dolan; M J Ferson; L M McGuinness; P R Brown; P W Robertson
Journal:  Med J Aust       Date:  1997-02-03       Impact factor: 7.738

4.  Hepatitis infection among adolescents resident in Melbourne Juvenile Justice Centre: risk factors and challenges.

Authors:  E L Ogilvie; F Veit; N Crofts; S C Thompson
Journal:  J Adolesc Health       Date:  1999-07       Impact factor: 5.012

5.  Modelling hepatitis C virus incidence, prevalence and long-term sequelae in Australia, 2001.

Authors:  Matthew G Law; Gregory J Dore; Nicky Bath; Sandra Thompson; Nick Crofts; Kate Dolan; Wendy Giles; Paul Gow; John Kaldor; Stuart Loveday; Elizabeth Powell; Jenean Spencer; Alex Wodak
Journal:  Int J Epidemiol       Date:  2003-10       Impact factor: 7.196

6.  A randomised controlled trial of methadone maintenance treatment versus wait list control in an Australian prison system.

Authors:  Kate A Dolan; James Shearer; Margaret MacDonald; Richard P Mattick; Wayne Hall; Alex D Wodak
Journal:  Drug Alcohol Depend       Date:  2003-10-24       Impact factor: 4.492

7.  Hepatitis C virus infection among a cohort of Victorian injecting drug users.

Authors:  N Crofts; J L Hopper; D S Bowden; A M Breschkin; R Milner; S A Locarnini
Journal:  Med J Aust       Date:  1993-08-16       Impact factor: 7.738

8.  Hepatitis C transmission and HIV post-exposure prophylaxis after needle- and syringe-sharing in Australian prisons.

Authors:  Belinda G O'Sullivan; Michael H Levy; Kate A Dolan; Jeffrey J Post; Sharon G Barton; Dominic E Dwyer; John M Kaldor; Andrew E Grulich
Journal:  Med J Aust       Date:  2003-06-02       Impact factor: 7.738

9.  Clearance of hepatitis C viremia associated with cellular immunity in the absence of seroconversion in the hepatitis C incidence and transmission in prisons study cohort.

Authors:  Jeffrey J Post; Yong Pan; Anthony J Freeman; Charles E Harvey; Peter A White; Patricia Palladinetti; Paul S Haber; George Marinos; Michael H Levy; John M Kaldor; Kate A Dolan; Rosemary A Ffrench; Andrew R Lloyd; William D Rawlinson
Journal:  J Infect Dis       Date:  2004-04-26       Impact factor: 5.226

10.  Spread of bloodborne viruses among Australian prison entrants.

Authors:  N Crofts; T Stewart; P Hearne; X Y Ping; A M Breshkin; S A Locarnini
Journal:  BMJ       Date:  1995-02-04
View more
  8 in total

1.  Viral interactions with B-cells contribute to increased regulatory T-cells during chronic HCV infection.

Authors:  Chris L Ayers; Mihail Firan; Vinodh Pillai; William M Lee; Nitin J Karandikar
Journal:  Viral Immunol       Date:  2011-04       Impact factor: 2.257

2.  Prevalence, genotypes and factors associated with HCV infection among prisoners in Northeastern Brazil.

Authors:  Bruno Fernandes de Oliveira Santos; Nathalie Oliveira de Santana; Alex Vianey Callado Franca
Journal:  World J Gastroenterol       Date:  2011-07-07       Impact factor: 5.742

3.  Prevalence of HIV and hepatitis C virus infections among inmates of Ontario remand facilities.

Authors:  Liviana Calzavara; Nancy Ramuscak; Ann N Burchell; Carol Swantee; Ted Myers; Peter Ford; Margaret Fearon; Sue Raymond
Journal:  CMAJ       Date:  2007-07-31       Impact factor: 8.262

Review 4.  HIV and hepatitis B and C incidence rates in US correctional populations and high risk groups: a systematic review and meta-analysis.

Authors:  Ethan Gough; Mirjam C Kempf; Laura Graham; Marvin Manzanero; Edward W Hook; Al Bartolucci; Eric Chamot
Journal:  BMC Public Health       Date:  2010-12-21       Impact factor: 3.295

5.  Intravenous drug use and hepatitis C virus in iran.

Authors:  Mehdi Zobeiri; Peyman Adibi; Seyed Moayed Alavian
Journal:  Hepat Mon       Date:  2012-01-20       Impact factor: 0.660

6.  Incidence and correlates of hepatitis C virus infection in a large cohort of prisoners who have injected drugs.

Authors:  Kathryn J Snow; Jesse T Young; David B Preen; Nicholas G Lennox; Stuart A Kinner
Journal:  BMC Public Health       Date:  2014-08-11       Impact factor: 3.295

Review 7.  Status of HIV and hepatitis C virus infections among prisoners in the Middle East and North Africa: review and synthesis.

Authors:  Marieke Heijnen; Ghina R Mumtaz; Laith J Abu-Raddad
Journal:  J Int AIDS Soc       Date:  2016-05-27       Impact factor: 5.396

8.  Injection drug use is a risk factor for HCV infection in urban Egypt.

Authors:  Adela Paez Jimenez; Mostafa K Mohamed; Noha Sharaf Eldin; Hasnaa Abou Seif; Said El Aidi; Yehia Sultan; Nasr Elsaid; Claire Rekacewicz; Mostafa El-Hoseiny; May El-Daly; Mohamed Abdel-Hamid; Arnaud Fontanet
Journal:  PLoS One       Date:  2009-09-28       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.